“New Hope” of Kalydeco (VX-770) Makes Headlines and Newscasts Around the Nation
November 8, 2011
CNN, CBS News and the Los Angeles Times were among major media outlets that recently featured stories about Kalydeco™ (VX-770), and the promise of this potential CF drug, which is undergoing review for approval by the U.S. Food & Drug Administration.
The news coverage was inspired by the publication last week of data from the Phase 3 trial of Kalydeco in the New England Journal of Medicine, the world’s most widely read and influential medical periodical.
Kalydeco was developed by Vertex Pharmaceuticals, Inc., with Cystic Fibrosis Foundation support and research input. If approved, it will be the first drug on the market that targets the underlying cause of CF, rather than just the symptoms of the disease. The drug is for people with the G551D mutation of CF.
Chronicled in the Los Angeles Times is the story of one patient, Lindsay Shipp, who took part in the Kalydeco clinical trial. It wasn’t too long ago that Shipp, a 27-year-old singer and dancer, watched her dreams of performing on Broadway fade away.
Since participating in the Kalydeco clinical trial, she has experienced dramatic improvements in her health and is optimist about her future again.
“It's like there are someone else's lungs inside of me," Shipp said in the article. "It's awesome — I feel like I can do anything."
Read the L.A. Times story and other major media coverage here:
- Learn more about Kalydeco in these FAQs.